Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Frequently asked questions
What sector does Orexo AB (ORX) operate in?
Orexo AB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Orexo AB (ORX) current stock price?
As of the latest data, Orexo AB stock price is SEK 15.66, with a previous close of SEK 15.64. Orexo AB gained SEK 0.02 in the last trading session, representing a 0.13% increase.
What is Orexo AB (ORX) current market capitalization?
Orexo AB market cap is approximately 550.09 million.
What is Orexo AB (ORX) Earnings Per Share (EPS)?
The trailing EPS is -SEK 12.16, and the forward EPS is -SEK 7.21.
What is Orexo AB (ORX) EBITDA?
Orexo AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -95.00 million.
Does Orexo AB (ORX) pay dividends?
No. Orexo AB does not pay a dividend.
How did Orexo AB (ORX) perform in its most recent earnings report?
In the last report (June 30, 2026), Orexo AB posted an EPS surprise of -58.43% and a revenue surprise of -65.35%.
What is Orexo AB (ORX) beta (volatility) score?
Orexo AB has a beta of 0.887, meaning its volatility is roughly in line with the market.
